HROW · Harrow, Inc. · Executive Compensation
$30.63
+0.05 (+0.16%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$1.24B
Shares
37.49M
Volume · Oct 5
587.35K
Avg daily vol (3M)
564.49K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Mark L. Baum | Chief Executive Officer | $23,606,274 |
| Andrew R. Boll | President and Chief Financial Officer | $10,947,441 |
| Andrew Boll | CFO | $10,947,441 |
| Amir Shojaei | Chief Scientific Officer | $1,342,627 |
| Francis W. Mullery | President and Chief Executive Officer, ImprimisRx Division | $1,237,692 |
| John P. Saharek | Former President and Chief Executive Officer, ImprimisRx Division | $727,421 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark L. Baum | Chief Executive Officer | $1,358,490 |
| Andrew Boll | CFO | $849,201 |
| Andrew R. Boll | Chief Financial Officer and Corporate Secretary | $849,201 |
| John P. Saharek | President and Chief Executive Officer, ImprimisRx | $743,467 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark L. Baum | Chief Executive Officer | $15,256,463 |
| Andrew Boll | CFO | $7,130,409 |
| Andrew R. Boll | Chief Financial Officer and Corporate Secretary | $7,130,409 |
| John P. Saharek | President and Chief Executive Officer, ImprimisRx | $5,815,154 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Mark L. Baum | Chief Executive Officer | $1,195,141 |
| Andrew R. Boll | Chief Financial Officer and | $764,386 |
| Andrew Boll | CFO | $764,386 |
| John P. Saharek | Chief Commercial Officer; Chief Executive Officer and President, ImprimisRx | $656,887 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mark L. Baum | Chief Executive Officer | $7,321,467 |
| Andrew Boll | CFO | $3,352,154 |
| Andrew R. Boll | Chief Financial Officer and | $3,352,154 |
| John P. Saharek | Chief Commercial Officer and President, ImprimisRx | $2,676,858 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Mark L. Baum | Chief Executive Officer | $2,483,296 |
| Andrew Boll | CFO | $1,016,804 |
| Andrew R. Boll | Chief Financial Officer and Corporate Secretary | $1,016,804 |
| John P. Saharek | President, ImprimisRx | $533,538 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Mark L. Baum | Chief Executive Officer | $1,377,012 |
| Andrew R. Boll | Chief Financial Officer | $1,049,545 |
| Andrew Boll | CFO | $1,049,545 |
| John P. Saharek | President, ImprimisRx | $963,798 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Randall E. Pollard | Chief Accounting Officer and principal accounting officer | Terminated | 2026-09-04 |
| Patrick W. Sullivan | Chief Commercial Officer | Appointed | 2026-02-02 |
| Frank Mullery | Chief Executive Officer of ImprimisRx | Appointed | 2025-10-06 |
| Bridseida Cruz | Head of Quality of ImprimisRx | Appointed | 2025-10-06 |
| Randall E. Pollard | Chief Accounting Officer (principal accounting officer) | Appointed | 2025-08-25 |
| Andrew R. Boll | President | Appointed | 2025-08-25 |
| Marty A. Makary | member of the Company's Board | Resigned | 2025-01-21 |
| Lauren P. Silvernail | member of the Board | Appointed | 2024-01-29 |
| Adrienne L. Graves | member of the Board | Appointed | 2024-01-29 |
| John P. Saharek | President and Chief Executive Officer of the Company's ImprimisRx division | Appointed | 2024-01-03 |
| Perry J. Sternberg | member of the Audit Committee and Nomination and Corporate Governance Committee | Appointed | 2023-11-03 |
| Martin A. Makary | member of the Compensation Committee and Nomination and Corporate Governance Committee | Appointed | 2023-11-03 |
| R. Lawrence Van Horn | member of the Company's Board | Resigned | 2023-11-03 |